Scholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 13,112 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 13,112 shares of the stock in a transaction on Wednesday, January 14th. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40. Following the transaction, the insider directly owned 108,964 shares in the company, valued at approximately $4,925,172.80. The trade was a 10.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mo Qatanani also recently made the following trade(s):

• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Trading Down 3.4%

Shares of Scholar Rock stock opened at $44.97 on Friday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a twelve month low of $22.71 and a twelve month high of $48.28. The firm has a market capitalization of $4.59 billion, a PE ratio of -14.28 and a beta of 0.63. The firm’s 50-day moving average price is $42.34 and its 200 day moving average price is $36.94.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter last year, the business earned ($0.66) earnings per share. On average, sell-side analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently bought and sold shares of SRRK. Three Seasons Wealth LLC increased its holdings in shares of Scholar Rock by 2.1% during the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock worth $483,000 after buying an additional 222 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Scholar Rock by 7.9% in the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock valued at $231,000 after acquiring an additional 456 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Scholar Rock by 15.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company’s stock worth $130,000 after acquiring an additional 500 shares during the period. California State Teachers Retirement System raised its position in Scholar Rock by 0.9% in the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after purchasing an additional 577 shares during the period. Finally, Tema Etfs LLC raised its position in Scholar Rock by 6.6% in the fourth quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock valued at $436,000 after purchasing an additional 616 shares during the period. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Truist Financial dropped their target price on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating for the company in a report on Monday, October 20th. Piper Sandler dropped their price objective on shares of Scholar Rock from $52.00 to $51.00 and set an “overweight” rating for the company in a research note on Wednesday, September 24th. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Friday, November 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Finally, JPMorgan Chase & Co. upped their price target on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $50.14.

Scholar Rock News Summary

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Several sell-side firms have maintained or raised constructive ratings and price targets (consensus ~ $50+), which supports longer-term interest in the name.
• Positive Sentiment: Large institutional positions and recent additions (e.g., Norges Bank, other funds) mean professional investors are committed to SRRK, which can support the share base despite short-term volatility.
• Neutral Sentiment: Company fundamentals: Scholar Rock is a clinical-stage biotech focused on growth-factor biology (lead program SRK‑015 for SMA). It has strong liquidity metrics (high current/quick ratios), which reduces near‑term financing risk.
• Negative Sentiment: CEO David Hallal sold 57,450 shares at ~$42.70 on Jan 13 — a large single insider sale that can be interpreted negatively by the market. CEO Form 4
• Negative Sentiment: COO Keith Woods sold 16,746 shares (~$42.70) on Jan 13. Aggregate exec selling increases perceived near-term supply pressure. COO Form 4
• Negative Sentiment: CFO Vikas Sinha sold 16,755 shares (~$42.70) on Jan 13, and other insiders including Akshay Vaishnaw and Mo Qatanani also reduced positions in mid‑January — the cluster of senior-level sales is likely the main driver of today’s weakness. CFO Form 4 Vaishnaw Form 4 Qatanani Form 4
• Negative Sentiment: Prior quarterly EPS (Nov 14) missed estimates modestly, which keeps upside tied to clinical progress and future data rather than near-term earnings.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).